Bipolar I and II disorders; A systematic review and meta-analysis on differences in comorbid obsessive-compulsive disorder by Amerio, Andrea et al.
Iran J Psychiatry Behav Sci. 2016 September; 10(3):e3604.
Published online 2016 August 17.
doi: 10.17795/ijpbs-3604.
Review Article
Bipolar I and II Disorders; A Systematic Review and Meta-Analysis on
Differences in Comorbid Obsessive-Compulsive Disorder
Andrea Amerio,1,2,* Brendon Stubbs,3 Anna Odone,4,5 Matteo Tonna,6 Carlo Marchesi,6 and S. Nassir
Ghaemi2,7
1Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
2Mood Disorders Program, Tufts Medical Center, Boston, MA, USA
3Institute of Psychiatry, Kings College London, London, UK
4School of Medicine-Public Health Unit, University of Parma, Parma, Italy
5Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
6Department of Mental Health, Local Health Service, Parma, Italy
7Tufts University Medical School, Department of Psychiatry and Pharmacology, Boston, MA, USA
*Corresponding author: Andrea Amerio, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy. Tel: +39-0521903594, Fax: +39-0521347047,
E-mail: andrea.amerio@studenti.unipr.it
Received 2015 July 21; Revised 2016 January 31; Accepted 2016 July 23.
Abstract
Context: More than half of the bipolar disorder (BD) cases have an additional diagnosis; one of the most difficult to manage is
obsessive-compulsive disorder (OCD). Although some authors recently investigated the co-occurrence of anxiety and BD, the topic
remains insufficiently studied. The current study aimed to investigate differences in comorbid OCD between BD-I and BD-II.
Evidence Acquisition: A systematic review and meta-analysis was conducted on the prevalence and predictors of comorbid BD-
I/BD-II and OCD. Relevant papers published until June 30, 2015 were identified searching the electronic databases MEDLINE, Embase,
PsycINFO and the Cochrane Library.
Results: Fourteen articles met the inclusion criteria. The pooled prevalence of BD-I in OCD was 3.9% (95% confidence interval (CI),
2.4 to 6.4, I2 = 83%, Q = 56) while that of BD-II in OCD was 13.5% (95% CI, 9.3 to 19.3, I2 = 89%, Q = 91). The pooled prevalence of OCD in
BD-I was 21.7 (95% CI, 4.8 to 60.3, I2 = 84%, Q = 95). With regard to OCD-BD predictors, mean age and rate of males did not predict the
prevalence of BD-I (β = 0.0731, 95% CI, -0.1097 to 0.256, z = 0.78; β = 0.035, 95% CI, -0.2356 to 0.1656, z = 0.34) and BD-II (β = 0.0577,
95% CI, -0.1942 to 0.0788, z = 0.83;β = -0.0317, 95% CI, -0.1483 to 0.085, z = 0.53) in OCD. The mean age explained some of the observed
heterogeneity (R2 = 0.13; R2 = 0.08).
Conclusions: This first systematic review and meta-analysis of the prevalence and predictors of comorbid BD-I/BD-II and OCD sug-
gests that BD-OCD comorbidity is a common condition in psychiatry. However, the available evidence does not allow to assess
whether BD-I or BD-II are more common in patients with OCD.
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1. Context
In a classic 1970 publication, the famous epidemiol-
ogist Alvan R. Feinstein defined comorbidity regarding a
specific index condition, as any distinct additional entity
that exists or may occur during the clinical course of a pa-
tient with the index disease under study (1). In the Fein-
stein formula, the implication was a different and indepen-
dent disease occurred at the same time as another disease.
On the contrary, the diagnostic and statistical manual
of mental disorders (DSM) explicitly produces overlapping
clinical criteria for many diagnoses, especially mood and
anxiety disorders, guaranteeing comorbidity in a quite dif-
ferent sense than in the medical meaning of the term as co-
occurrence of independent diseases.
Psychiatric comorbidity is extremely common in bipo-
lar disorder (BD). More than half of patients with BD have
an additional disorders (2), one of the most difficult to
manage is obsessive-compulsive disorder (OCD) (3-5).
However, although some authors recently investigated
the co-occurrence of anxiety and BD, no meta-analysis re-
garding the prevalence or sub-group analyses specific to
BD-I and BD-II were performed (6).
The present paper is the first systematic review and
meta-analysis on the prevalence and predictors of comor-
bid BD-I/BD-II and OCD.
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2. Objectives
The current review upgraded a previous systematic re-
view and performed a meta-analysis to define the preva-
lence and predictors of comorbid BD-I/BD-II and OCD.
3. Data Sources
As done before (7), the review was conducted accord-
ing to the methods recommended by the Cochrane collab-
oration (8) and the meta-analysis of observational studies
in epidemiology (MOOSE) guidelines (9), and documented
the process and results in accordance with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) guidelines (10).
3.1. Information Sources and Search Strategy
Studies were identified searching the electronic
databases MEDLINE, Embase, PsycINFO and the Cochrane
Library. Authors combined the search strategy of free
text terms and exploded MESH headings for the topics
of bipolar disorder and obsessive-compulsive disorder
combined as follows: bipolar disorderor (BD), bipolar
or manic depressive disorder, manic depressive, manic
and obsessive-compulsive disorder (OCD), obsessive-
compulsive. The strategy was first developed in MEDLINE
and then adaptedto the other databases (appendix 1. in
supplementary file). Studies published in English untill
June 30, 2015 were included. In addition, further studies
were retrieved from reference listing of relevant articles
and consultation with experts in the field.
3.2. Inclusion Criteria
3.2.1. Study Population and Study Design
The studies that included subjects with BD and OCD
with specified diagnostic criteria were considered. Stud-
ies that considered subjects with bipolar and obsessive-
compulsive spectrums with specified diagnostic criteria
were also included (11, 12). Participants of both genders
older than six years were considered. Studies conducted
on subjects with physical comorbidities were excluded as
non-representative of the study population (13, 14).
Both population- and hospital-based studies were
included. Among hospital-based studies, inpatients,
day-hospital and outpatient subjects were included
while emergency care records were excluded as non-
representative. All experimental and observational study
designs were included apart from case reports. Narrative
and systematic reviews, letters to the editor and book
chapters were excluded.
3.2.2. Outcome Measures
Primary outcomes were i) lifetime prevalence of co-
morbid OCD in patients with BD-I/BD-II and ii) lifetime
prevalence of comorbid BD-I/BD-II in patients with OCD.
Studies that reported data only about the current preva-
lence were excluded (15). Secondary outcomes were poten-
tial predictors of comorbidity between BD-I/BD-II and OCD.
4. Study Selection andData Extraction
Identified studies were independently reviewed for eli-
gibility by two authors in a two-step process; a first screen-
ing was performed based on title and abstract while full
texts were retrieved for the second screening. At both
stages disagreements by reviewers were resolved by con-
sensus. Data were extracted by one author and supervised
by a second one using an ad-hoc developed data extraction
spreadsheet. The data extraction spreadsheet was piloted
on 10 randomly selected papers and modified accordingly.
4.1. Quality Assessment
The same authors who performed data extraction in-
dependently assessed the quality of selected studies using
the checklist developed by Downs and Black, both for ran-
domised and non-randomised studies (16). Disagreements
by reviewers were resolved by consensus. Table 1 shows the
quality assessment total score assigned to each study.
4.2. Meta-Analysis
Individual study data were pooled using DerSimonian-
Laird method (29) with comprehensive Meta-Analysis soft-
ware ver. 3. Due to the anticipated heterogeneity, a ran-
dom effects meta-analysis was employed. First, the data
on the prevalence of BD-I and BD-II in patients with OCD
were pooled separately; next the data on the prevalence
of OCD in patients with BD-I and BD-II were pooled sep-
arately. Heterogeneity was assessed with the I2 and Q
statistic for each analysis. Further, meta-regression analy-
ses were conducted to investigate potential moderators if
available data included (mean age, rate of males and du-
ration of illness) with comprehensive Meta-Analysis ver. 3.
Publication bias was assessed with a visual inspection of
funnel plots (8), the Begg-Mazumdar Kendall’s tau (30) and
the Egger test (31).
5. Results
One thousand and two hundred eighty-two potential
studies were identified by searching the selected databases
and listing references of relevant articles. After remov-
ing duplicates, 894 articles were retrieved. Studies were
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Table 1. Studies Met the Inclusion Criteria for Systematic Review
References Study Design Country Study Population Sample Size Diagnosis Assessment Quality a
Population-Based
Studies
Angst, J. et al. 2004 (11) Prospective cohort study Switzerland 591 subjects recruited at
age 19/20 and assessed over
20 years: OCD (n = 30)
30 Broad definition for BD
and OCD; DSM-IV
26/31
Hospital-Based Studies:
Adults
Bogetto, F. et al. 1999 (16) Case-control study Italy OCD (n = 160, mean age:
males 32.1± 13.0, females
36.9± 11.4 years)
160 NS; DSM-IV 21/31
Dilsaver, S.C. et al. 2008
(17)
Case-control study USA 187 Latino pt. enrolled
consecutively from 2001 to
2003: BD-I (n = 69, mean
age = 34.9± 11.8 years)
69 SCID-CV; DSM-IV 20/31
Hantouche, E.G. et al.
2003 (18)
Case-control study France OCD (n = 628, mean age
CYC-OCD = 35± 12, mean
age NC-OCD = 36± 14
years)
628 NS; DSM-IV 24/31
Kim, S.W. et al. 2014 (19) Cross-sectional study South Korea BD-I (n = 174, age > 18 years) 174 SCID; DSM-IV 22/31
Lensi, P. et al. 1996 (20) Case-control study Italy OCD (n = 263, mean age =
33.1 years)
263 NS; DSM-III-R 21/31
Maina, G. et al. 2007 (21) Case-control study Italy OCD (n = 204, mean age =
34.7± 12.1 years)
204 SCID; DSM-IV 21/31
Marazziti, D. et al. 2002
(22)
Cross-sectional study Italy OCD (n = 117, mean age=30
± 9.3 years)
117 SCID-P; DSM-IV 21/31
Perugi, G. et al. 1997 (23) Case-control study Italy OCD (n = 315, mean age:
BD-OCD = 32.8± 12.2, OCD
= 32.5± 12.6 years)
345 NS; DSM-III-R 22/31
Perugi, G. et al. 1998 (24) Case-control study Italy OCD (n = 135, mean age =
38.4± 13.3 years)
135 NS; DSM-III-R 21/31
Perugi, G. et al. 1999 (25) Case-control study Italy 269 pt. enrolled
consecutively from 1993 to
1995: OCD (n = 79, mean
age = 30.4± 11.8 years)
79 SCID-Up-R; DSM-III-R 20/31
Perugi, G. et al. 2002 (26) Case-control study Italy OCD-MDE (n = 68, mean
age = 34.2± 12.5 years);
BD-OCD (n = 38, mean
age=35.9± 12.2 years)
68 SCID; DSM-IV 20/31
Shashidhara, M. et al.
2015 (27)
Cross-sectional study India BD-I (n = 396, age > 18
years)
396 SCID; DSM-IV 23/31
Timpano, K.R. et al. 2012
(28)
Case-control study USA OCD (n = 605, mean age =
39.2 years)
605 SCID-P; DSM-IV 20/31
Abbreviations: BD: bipolar disorder; BD-I: bipolar disorder type I; OCD: obsessive-compulsive disorder; MDE: major depressive episode; NS: not specified; Pt.: patients;
DSM: diagnostic and statistical manual of mental disorders; SCID: structured clinical interview; SCID-P: structured clinical interview patient version; SCID-CV: structured
clinical interview clinical version; SCID-Up-R: structured clinical interview Upjohn version.
aChecklist for measuring study quality developed by Downs and Black.
screened and selected on the basis of pre-specified inclu-
sion and exclusion criteria (Figure 1). The search identified
14 articles appropriate to be included in the systematic re-
view: three articles about comorbid OCD in BD-I (8, 22, 31)
and eleven articles about comorbid BD-I/BD-II in OCD (12, 17,
19, 21-27, 32).
5.1. Comorbid BD in OCD
5.1.1. Study Characteristics
The characteristics of included studies are reported in
Table 1. Nine of the eleven studies were case-control stud-
ies, one cross-sectional study and one prospective cohort
study. One study (9%) was population-based while the ma-
jority (n = 10, 91%) were hospital-based. Totally, 2,634 pa-
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Figure 1. Flow Diagram of Selected Articles. *Search strategy limited to June 2015, English language and human subjects older than six years old
tients with OCD were represented among the eleven in-
cluded studies. The mean age of patients with OCD was 34.7
± 2.96 years and 43.8% were male (36.6%-50%). The major-
ity of the studies were conducted in Europe (n = 9, 82%). In
all the considered studies, diagnosis of BD-I/BD-II and OCD
were based on the DSM criteria and they were established
using validated assessment scales.
5.2. Meta-analysis of the pooled prevalence of BD-I/BD-II in pa-
tients with OCD
It was possible to pool data from 2,444 patients with
OCD across 10 studies to found the prevalence of BD-I as
3.9% (95% CI, 2.4 to 6.4, I2 = 83%, Q = 56) (Figure 2A). Begg
(tau = 1, P = 0.4) or Egger (intercept = -2.9, P = 0.19) did not
indicate any evidence of publication bias.
It was possible to pool data from 2,634 patients with
OCD across 12 studies to found the prevalence of BD-II as
13.5% (95% CI, 9.3 to 19.3, I2 = 89, Q = 91) (Figure 2B). There
was no evidence of publication bias (Begg = 1.7, P = 0.2; Eg-
ger = 4.8, P = 0.15).
5.3. Predictors of the Prevalence of BD-I/BD-II in Patients with
OCD
Mean age did not predict the prevalence of BD-I in OCD
(β = 0.0731, 95% CI, -0.1097 to 0.256, z = 0.78), but it did
explain some of the observed heterogeneity (R2 = 0.13).
The rate of males did not moderate the prevalence of BD-
I (β = 0.035, 95% CI, 0.2356 to 0.1656, z = -0.34). Mean age
did not moderate the prevalence of BD-II (β = -0.0577, 95%
CI, -0.1942 to 0.0788, z = -0.83), but it did explain a small
amount of the observed heterogeneity (R2 = 0.08). More-
over, the rate of males was not related to the prevalence of
BD-II (β = -0.0317, 95% CI, -0.1483 to 0.085, z =-0.53).
5.4. Comorbid OCD in BD
5.4.1. Study Characteristics
The characteristics of the included studies are reported
in Table 1. Two studies were cross-sectional and one case-
control. All the studies were hospital-based and conducted
in non-European countries. Totally, 639 patients with BD-
I were evaluated in the three included studies. The mean
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1.00 Perugi, G. et al. 2002 (31) 0.176 0.103 0.286
1.00 Timpano, K. R. et al. 2012 (32) 0.084 0.065 0.109
1.00 Marazziti, D. et al. 2002 (27) 0.051 0.023 0.109
1.00 Perugi, G. et al. 1999 (30) 0.038 0.012 0.111
1.00 Hantouche, E. G.. et al. 2003 (24) 0.030 0.019 0.047
1.00 Perugi, G. et al. 1997 (28) 0.020 0.010 0.042
1.00 Maina, G. et al. 2007 (26) 0.020 0.007 0.051
1.00 Lensi, P. et al. 1996 (25) 0.015 0.006 0.040
1.00 Perugi, G. et al. 1998 (29) 0.015 0.004 0.057
1.00 0.038 0.021 0.068
Overall 0.038 0.021 0.068
-0.50 -0.25 0.00 0.25 0.50
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Study Name Statistics for Each Study Event Rate and 95% CI
Event Lower Upper 
Rate Limit Limit
2.00 Perugi, G. et al.. 2002 (31) 0.382 0.275 0.502
2.00 Angst, J. et al. 2004 (22) 0.300 0.164 0.483
2.00 Perugi, G. et al.. 1998 (29) 0.178 0.122 0.252
2.00 Perugi, G. et al.. 1999 (30) 0.177 0.108 0.277
2.00 Marazziti, D. et al.. 2002 (27) 0.154 0.099 0.231
2.00 Perugi, G. et al.. 1997 (28) 0.136 0.104 0.177
2.00 Lensi, P. et al.. 1996 (25) 0.122 0.087 0.167
2.00 Maina, G. et al.. 2007 (26) 0.083 0.052 0.130
2.00 Hantouche, E. G. et al. 2003 (24) 0.080 0.061 0.104
2.00 Bogetto, F. et al. 1999 (23) 0.069 0.038 0.120
2.00 Timpano, K. R. et. al. 2012 (32) 0.056 0.040 0.078
2.00 0.135 0.095 0.188
Overall 0.135 0.095 0.188
-0.50 -0.25 0.00 0.25 0.50
Figure 2. A, Pooled prevalence of bipolar disorder type-I in patients with obsessive-compulsive disorder; B, Pooled prevalence of bipolar disorder type-II in Patients with
obsessive-compulsive disorder.
age of patients with BD was 36.8± 5.8 years and 45% were
male (36% - 60.5%). In all the considered studies, diagnosis
of BD-I and OCD were based on the DSM criteria and were
established using validated assessment scales.
5.5. Meta-analysis of the pooled prevalence of OCD in patients
with BD-I
It was possible to pool data from three studies with 639
patients with BD-I, establishing a pooled prevalence of OCD
at 21.7% (95% CI, 4.8 to 60.3, Q = 95, I2 = 84%) (Figure 3). Egger
(intercept = 48, P = 0.2) and Begg (tau = 0.66, P = 0.29) did
not indicate any publication bias.
6. Discussion
The entire question of comorbidity deserves attention,
provided separately (33-36). In a standard 1969 psychia-
try textbook, Mayer-Gross et al., mostly considering the
course of illness, included patients with BD-OCD in the
manic-depressive disorders (37). Although recent studies
investigated the co-occurrence of anxiety and bipolar dis-
orders, the topic is insufficiently studied and the relation-
ship between BD and OCD remains unclear. However, given
the available scientific evidence, some observations can be
made.
Apparent BD-OCD comorbidity is a common condition
in psychiatry. In the authors’ recent meta-analysis, the
pooled prevalence of OCD in BD was 17.0% (95% CI, 12.7 to
22.4), which was comparable to the results reported by the
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Study Name Event Rate and 95% CI
Event Lower Upper 
Rate Limit Limit
Dilsaver, S. C. et al. 2008 (19) 0.623 0.504 0.729
Kim, S.W. et al. 2014 (20) 0.138 0.094 0.198
Shashidhara, M. et al. 2015 (21) 0.076 0.053 0.106
0.217 0.048 0.603
-1.00 -0.50 0.00 0.50 1.00
Figure 3. Pooled Prevalence of Obsessive-Compulsive Disorder in Patients with Bipolar Disorder Type-I
pooled prevalence of BD in OCD (18.35%, 95% CI, 13.2 to 24.8)
(33). Although limited by the retrospective study design,
small sample size, different thresholds for BD diagnosis
and a different accuracy in diagnosing OCD, these results
suggest the relevance of comorbid BD-OCD.
The current meta-analysis found that the pooled preva-
lence of BD-I in OCD was 3.9% (95% CI, 2.4 to 6.4, I2 = 83%, Q
= 56); while the pooled prevalence of BD-II in OCD was 13.5%
(95% CI, 9.3 to 19.3, I2 = 89%, Q = 91). The pooled prevalence
of OCD in BD-I was 21.7% (95% CI, 4.8 to 60.3, I2 = 84%, Q =
95). With regard to OCD-BD predictors, mean age and rate
of males did not predict the prevalence of BD-I (β = 0.0731,
95% CI, -0.1097 to 0.256, z = 0.78; β = 0.035, 95% CI, -0.2356
to 0.1656, z = -0.34) and BD-II (β = -0.0577, 95% CI, -0.1942
to 0.0788, z = -0.83; β = -0.0317, 95% CI, -0.1483 to 0.085, z
=-0.53) in OCD. Mean age explained some of the observed
heterogeneity (R2 = 0.13; R2 = 0.08).
From the nosological perspective, considering the
course of illness as a key diagnostic validator, especially
among patients with a primary diagnosis of BD, the ma-
jority of cases with comorbid OCD appeared to be related
to mood episodes (34). OC symptoms in patients with co-
morbid OCD appeared more often - and sometimes exclu-
sively - during depressive episodes, and comorbid BD and
OCD cycled together, with OC symptoms often remitting
during manic/hypomanic episodes. On the contrary, es-
pecially among patients with a primary diagnosis of OCD,
there was a substantial minority of comorbid BD-OCD that
may represent true OCD separate from BD with OC symp-
toms that improve or worsen during mood episodes with-
out being related to them.
Results of the authors recent meta-analysis showed
higher comorbidity rates in youths (24.2%, 95% CI, 10.36 to
41.60, n = 345, z =-9.5) compared to adults (13.56%, 95% CI,
10.4 to 16.25, n = 4,539) (33). In other words, OC symptoms
would initially coexist with BD symptoms and they would
gradually tend to decrease in the adulthood (38, 39).
From a neurobiological perspective, BD mostly showed
hypoactivity in orbitofrontal cortex (OFC) (i e, decision
making, impulse control) and in dorsolateral prefrontal
cortex (DLPFC) (i e, planning, attentional set shifting)
with grey matter volume reduction associated to manic
episodes (40), while OCD mainly presented hyperactivity
of OFC with deficit in emotional processing (41). The over-
lap of similar cortical-subcortical circuits may partially ex-
plain the clinical features of patients with comorbid BD-
OCD during the course of illness.
The clinical features of patients with comorbid BD-OCD
would explain why OCD and BD symptoms respond to ad-
equate mood stabilizer treatment (4, 6). Only in a minor-
ity of patients with persistent comorbid OCD, despite im-
provement in mood episodes, addition of low doses of an-
tidepressants could be considered while strictly monitor-
ing emerging symptoms of mania or mixed states (4). Ben-
efit with neuroleptics was also observed, although a few
reports of exacerbation of OC symptoms with neuroleptic
agents existed (4). Deep brain stimulation also seems to
carry risks of manic worsening, and thus may not be a use-
ful intervention in BD-OCD (4).
Further original studies are needed to clarify BD-OCD
comorbidity. In particular, considering the growing in-
terest over the last decades in shared pathophysiologies
across psychiatric disorders (42), studies addressing neu-
robiological substrates are essential to illuminate patho-
genetic mechanisms that underlie comorbid BD-OCD.
6.1. Limitations
The main limitation of this systematic review is linked
to the study design and analysis strategy of the included
studies, as documented in the quality assessment scale
used. Most studies were observational and based on ret-
rospective assessments. The use of retrospective assess-
ment scales with low sensitivity in discriminating true
ego-dystonic obsessions from depressive ruminations may
have biased results towards an overestimation of obses-
sive symptom prevalence. Some of them did not include
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a control group. Small sample size and enrollment of sub-
jects mainly from BD-OCD outpatient units may limit gen-
eralizability of these results. Potential confounding fac-
tors in these studies include demographic and historical
illness variables, which often were not appropriately ana-
lyzed through multivariate modelling. In particular, some
analyses contained few studies (e g, OCD in BD I, three stud-
ies), and in such instances, the publication bias tests used
may be insensitive to potential publication bias.
The main strength of this review is being systematic
and including the entire scientific evidence published so
far in the main medical databases. The strength of the se-
lected studies was that the diagnosis of BD and OCD were
consistently based on the DSM criteria and were estab-
lished by trained investigators using validated assessment
scales mainly with inter-rater reliability (IRR).
SupplementaryMaterial
Supplementary material(s) is available here.
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